Business Summary
- research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.;
- production of pharmaceutical active ingredients (5.1%).
Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).
Number of employees: 1,505
Managers
Managers | Title | Age | Since |
---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 44 | - |
Director of Finance/CFO | 64 | 02-12-31 | |
Dmitry Saikovky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Eric Ivanovsky
CTO | Chief Tech/Sci/R&D Officer | - | - |
Andrejs Liberts
PRN | Corporate Officer/Principal | 39 | 21-02-23 |
Iveta Zomerfelde
SAM | Sales & Marketing | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kirovs Lipmans
CHM | Chairman | 83 | 02-12-31 |
Anna Lipmane
BRD | Director/Board Member | 76 | 07-12-31 |
Filips Lipmans
BRD | Director/Board Member | 46 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 9,585,000 | 308,478 ( 3.218 %) | 0 | 3.218 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+19.62% | 43.34B | |
+20.44% | 21.96B | |
+10.86% | 14.09B | |
+13.07% | 13.64B | |
+37.46% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |